

# 1                    **Researching COVID to enhance recovery (RECOVER) pregnancy study:**

## 2    **Rationale, objectives and design**

### 3    **Short Title: RECOVER Pregnancy Cohort Protocol**

4

5    Torri D. Metz<sup>1\*</sup>; Rebecca G. Clifton<sup>2</sup>; Richard Gallagher<sup>3</sup>; Rachel S. Gross<sup>4</sup>; Leora I. Horwitz<sup>5</sup>;  
6    Vanessa L. Jacoby<sup>6</sup>; Susanne P. Martin-Herz<sup>7</sup>; Myriam Peralta-Carcelen<sup>8</sup>; Harrison T. Reeder<sup>9</sup>;  
7    Carmen J. Beamon<sup>10</sup>; Marie-Abele Bind<sup>9</sup>; James Chan<sup>9</sup>; A. Ann Chang<sup>11</sup>; Lori B. Chibnik<sup>9</sup>;  
8    Maged M. Costantine<sup>12</sup>; Megan L. Fitzgerald<sup>5</sup>; Andrea S. Foulkes<sup>9</sup>; Kelly S. Gibson<sup>13</sup>; Nick  
9    Güthe<sup>5</sup>; Mounira Habli<sup>14</sup>; David N. Hackney<sup>15</sup>; Matthew K. Hoffman<sup>16</sup>; M. Camille Hoffman<sup>17</sup>;  
10   Brenna L. Hughes<sup>18</sup>; Stuart D. Katz<sup>19</sup>; Victoria Laleau<sup>20</sup>; Gail Mallett<sup>21</sup>; Hector Mendez-  
11   Figueroa<sup>22</sup>; Vanessa Monzon<sup>6</sup>; Anna Palatnik<sup>23</sup>; Kristy T.S. Palomares<sup>24</sup>; Samuel Parry<sup>25</sup>;  
12   Myriam Peralta-Carcelen<sup>8</sup>; Christian M. Pettker<sup>26</sup>; Beth A. Plunkett<sup>27</sup>; Athena Poppas<sup>28</sup>; Uma M.  
13   Reddy<sup>29</sup>; Dwight J. Rouse<sup>30</sup>; George R. Saade<sup>31</sup>; Grecio J. Sandoval<sup>32</sup>; Shannon M. Schlater<sup>33</sup>;  
14   Frank C. Scurba<sup>34</sup>; Hyagriv N. Simhan<sup>35</sup>; Daniel W. Skupski<sup>36</sup>; Amber Sowles<sup>1</sup>; Tanayott  
15   Thaweethai<sup>9</sup>; Gelise L. Thomas<sup>37</sup>; John M. Thorp, Jr.<sup>38</sup>; Alan T. Tita<sup>39</sup>; Steven J. Weiner<sup>2</sup>;  
16   Samantha Weigand<sup>40</sup>; Lynn M. Yee<sup>21</sup>; Valerie J. Flaherman<sup>20</sup> on behalf of the RECOVER  
17   Initiative<sup>^</sup>

#### 18

#### 19    **Affiliations:**

20    <sup>1</sup>Department of Obstetrics and Gynecology, University of Utah Health Hospitals and Clinics, Salt  
21    Lake City, UT, USA.

22    <sup>2</sup>Biostatistics Center, The George Washington University, Washington, DC, USA.

23    <sup>3</sup>Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New  
24    York, NY, USA.

25 <sup>4</sup>Department of Pediatrics, New York University Grossman School of Medicine, New York, NY,  
26 USA.

27 <sup>5</sup>Department of Population Health, New York University Grossman School of Medicine, New  
28 York, NY, USA.

29 <sup>6</sup>Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California,  
30 San Francisco, San Francisco, CA, USA.

31 <sup>7</sup>Department of Pediatrics, Division of Developmental Medicine, University of California San  
32 Francisco, San Francisco, CA, San Francisco, CA, USA.

33 <sup>8</sup>Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.

34 <sup>9</sup>Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA.

35 <sup>10</sup>Department of Maternal Fetal Medicine, WakeMed Health and Hospitals, Raleigh, NC, USA.

36 <sup>11</sup>Women's Health Research Clinical Center, University of California San Francisco, San  
37 Francisco, CA, USA.

38 <sup>12</sup>Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center,  
39 Columbus, OH, USA.

40 <sup>13</sup>Department of Obstetrics and Gynecology, The MetroHealth System, Cleveland, OH, USA.

41 <sup>14</sup>Division Maternal Fetal Medicine, Trihealth Good Samaritan Hospital Maternal Fetal Medicine,  
42 Cincinnati, OH, USA.

43 <sup>15</sup>Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center: UH  
44 Cleveland Medical Center, Cleveland, OH, USA.

45 <sup>16</sup>Department of Obstetrics and Gynecology, Christiana Care Health System, Newark, DE, USA.

46 <sup>17</sup>Department of Obstetrics & Gynecology, University of Colorado School of Medicine, Aurora,  
47 CO, USA.

48 <sup>18</sup>Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA.

49 <sup>19</sup>Department of Medicine, New York University School of Medicine, New York City, NY, USA.

50 <sup>20</sup>Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.

51 <sup>21</sup>Department of Obstetrics and Gynecology, Northwestern University Feinberg School of  
52 Medicine, Chicago, IL, USA.

53 <sup>22</sup>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas  
54 McGovern Medical School: The University of Texas Health Science Center at Houston John P  
55 and Katherine G McGovern Medical School, Houston, TX, USA.

56 <sup>23</sup>Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI,  
57 USA.

58 <sup>24</sup>Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Saint Peter's  
59 University Hospital, New Brunswick, NJ, USA.

60 <sup>25</sup>Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA.

61 <sup>26</sup>Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of  
62 Medicine, New Haven, CT, USA.

63 <sup>27</sup>Department of Obstetrics and Gynecology, NorthShore University HealthSystem, Evanston,  
64 IL, USA.

65 <sup>28</sup>Division of Cardiology, Brown University Warren Alpert Medical School, PROVIDENCE, RI,  
66 USA.

67 <sup>29</sup>Department of Obstetrics and Gynecology, Columbia University, New York City, NY, USA.

68 <sup>30</sup>Department of Obstetrics and Gynecology, Brown University, Providence, RI, USA.

69 <sup>31</sup>Department of Obstetrics and Gynecology, The University of Texas Medical Branch at  
70 Galveston, Galveston, TX, USA.

71 <sup>32</sup>Biostatistics Center, The George Washington University, Rockville, MD, USA.

72 <sup>33</sup>Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA.

73 <sup>34</sup>Department of Medicine, Division of Pulmonary Allergy and Critical Care Medicine, University  
74 of Pittsburgh, pittsburgh, PA, USA.

75 <sup>35</sup>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh  
76 School of Medicine, Pittsburgh, PA, USA.

77 <sup>36</sup>Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.

78 <sup>37</sup>Clinical and Translational Science Collaborative of Cleveland, Case Western Reserve  
79 University, Cleveland, Ohio, Cleveland, OH, USA.

80 <sup>38</sup>Department of Obstetrics and Gynecology, UNC: The University of North Carolina at Chapel  
81 Hill, Chapel Hill, NC, USA.

82 <sup>39</sup>Department of Obstetrics and Gynecology, Center for Women's Reproductive Health,  
83 University of Alabama at Birmingham, Birmingham, AL, USA.

84 <sup>40</sup>Department of Obstetrics and Gynecology, Wright State University Boonshoft School of  
85 Medicine, Dayton, OH, USA.

86

87 \* Corresponding author

88 Email: [torri.metz@hsc.utah.edu](mailto:torri.metz@hsc.utah.edu) (TM)

89 ^Membership of the RECOVER Initiative is provided in the Acknowledgements.

90 Authorship has been determined according to ICMJE recommendations.

91 **Clinical Trials.gov Identifier:** Clinical Trial Registration: <http://www.clinicaltrials.gov>.

92 Unique identifier: NCT05172011

## 93 **Disclaimer**

94 The content is solely the responsibility of the authors and does not necessarily represent the  
95 official views of the RECOVER program, the NIH or other funders.

## 96 **Funding**

97           This research was funded by the National Institutes of Health (NIH) Agreement OTA  
98    OT2HL161841, OT2HL161847, and OT2HL156812 as part of the Researching COVID to  
99    Enhance Recovery (RECOVER) research Initiative. This content is solely the responsibility of  
100   the authors and does not necessarily represent the official views of the RECOVER Program or  
101   the NIH.

## 102 **Competing interests**

103           Dr. Metz reports personal fees from Pfizer for her role as a medical consultant for a  
104    SARS-CoV-2 vaccination in pregnancy study, grants from Pfizer for role as a site PI for SARS-  
105    CoV-2 vaccination in pregnancy study, grants from Pfizer for role as a site PI for RSV  
106    vaccination in pregnancy study, and grants from Gestvision for role as a site PI for a  
107    preeclampsia study outside the submitted work. Dr. Horwitz reported serving as a member of  
108    the National Academy of Medicine Committee on the Long-Term Health Effects Stemming from  
109    COVID-19 and Implications for the Social Security Administration. Dr. Costantine reported  
110    receiving grant support for work not related to this paper from Baxter International and Siemens  
111    Healthcare and personal consulting fees not related to this paper from Progenity and Siemens  
112    Healthcare.  
113    The other authors state that they have nothing to disclose.

114

## 115 **Abstract**

116 **Importance:** Pregnancy induces unique physiologic changes to the immune response  
117 and hormonal changes leading to plausible differences in the risk of developing post-acute  
118 sequelae of SARS-CoV-2 (PASC), or Long COVID. Exposure to SARS-CoV-2 during pregnancy  
119 may also have long-term ramifications for exposed offspring, and it is critical to evaluate the  
120 health outcomes of exposed children. The National Institutes of Health (NIH) Researching  
121 COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC aims to  
122 evaluate the long-term sequelae of SARS-CoV-2 infection in various populations. RECOVER-  
123 Pregnancy was designed specifically to address long-term outcomes in maternal-child dyads.

124 **Methods:** RECOVER-Pregnancy cohort is a combined prospective and retrospective  
125 cohort that proposes to enroll 2,300 individuals with a pregnancy during the COVID-19  
126 pandemic and their offspring exposed and unexposed in utero, including single and multiple  
127 gestations. Enrollment will occur both in person at 27 sites through the *Eunice Kennedy Shriver*  
128 National Institutes of Health Maternal-Fetal Medicine Units Network and remotely through  
129 national recruitment by the study team at the University of California San Francisco (UCSF).  
130 Adults with and without SARS-CoV-2 infection during pregnancy are eligible for enrollment in  
131 the pregnancy cohort and will follow the protocol for RECOVER-Adult including validated  
132 screening tools, laboratory analyses and symptom questionnaires followed by more in-depth  
133 phenotyping of PASC on a subset of the overall cohort. Offspring exposed and unexposed in  
134 utero to SARS-CoV-2 maternal infection will undergo screening tests for neurodevelopment and  
135 other health outcomes at 12, 18, 24, 36 and 48 months of age. Blood specimens will be  
136 collected at 24 months of age for SARS-CoV-2 antibody testing, storage and anticipated later  
137 analyses proposed by RECOVER and other investigators.

138           **Discussion:** RECOVER-Pregnancy will address whether having SARS-CoV-2 during  
139 pregnancy modifies the risk factors, prevalence, and phenotype of PASC. The pregnancy cohort  
140 will also establish whether there are increased risks of adverse long-term outcomes among  
141 children exposed in utero.

142   **Registration:** NCT05172024

143

## 144 Introduction

145 The disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-  
146 CoV-2), coronavirus disease 2019 (COVID-19), results in both short-term and long-term  
147 sequelae, and many people with COVID-19 experience persistent health effects for months  
148 beyond initial infection.<sup>1-4</sup> Thus, evidence regarding the post-acute sequelae of SARS-CoV-2  
149 (PASC) or “long COVID” is urgently needed to guide clinical care and inform public health  
150 policy.

151 Pregnant individuals may experience different long-term effects from COVID-19 than  
152 non-pregnant individuals due to the immunomodulatory effects of pregnancy. In a publication  
153 from the PRIORITY study consisting of pregnant individuals infected in 2020, 25% with COVID-  
154 19 experienced prolonged viral symptoms 8 weeks after infection, with median time to resolution  
155 of initial infection of 37 days.<sup>5</sup> Data beyond those first 8 weeks are not available. Thus, it  
156 remains unknown if there is a differential likelihood of PASC among individuals who contract  
157 SARS-CoV-2 during pregnancy compared with non-pregnant adults.

158 In addition, the offspring of patients with COVID-19 during pregnancy may be at  
159 increased risk of both short and long-term morbidity related to in utero exposure to SARS-CoV-  
160 2, resulting from inflammation and vascular changes in the placenta<sup>6</sup>, as evidenced by  
161 investigation of the effects of other viruses and in the setting of placental insufficiency. The  
162 effects of SARS-CoV-2 on the health of pregnant individuals and their offspring may vary based  
163 on SARS-CoV-2 variant, gestational age at infection, and maternal health and vaccination  
164 status.<sup>7-12</sup> Existing data demonstrate that the Delta variant results both in the highest risk of  
165 maternal critical illness and stillbirth, and in the most profound placental effects.<sup>7,8</sup> Vaccination  
166 has been found to be protective against both severe maternal COVID-19 and adverse  
167 pregnancy outcomes, and may also influence the incidence of PASC in this population.<sup>9-11</sup>



168           The National Institute of Health’s (NIH) RECOVER initiative has a unique opportunity to  
169 study the post-acute sequelae of SARS-CoV-2 acquired in pregnancy. RECOVER-Pregnancy  
170 will enroll maternal-child dyads to investigate the effects of SARS-CoV-2 acquired during  
171 pregnancy on the long-term health of both the pregnant person and their offspring who were  
172 exposed to SARS-CoV-2 in utero. We hypothesize that the incidence of persistent long-term  
173 sequelae among pregnant people will vary from that of non-pregnant adults given the unique  
174 changes in physiology, hormone levels, and inflammatory milieu in pregnancy. In addition, we  
175 hypothesize that the offspring of individuals with SARS-CoV-2 infection in pregnancy will have  
176 worse developmental outcomes when compared with unexposed offspring delivered over the  
177 same time period. The overarching goal of RECOVER-Pregnancy is to describe PASC in  
178 people who are infected with SARS-CoV-2 in pregnancy and examine the outcomes of their  
179 offspring compared with children who were not exposed to SARS-CoV-2 in utero.

## 180 **Materials and Methods**

### 181 **Objectives**

182           RECOVER-Pregnancy cohort will enroll maternal-child dyads exposed and unexposed  
183 to SARS-CoV-2 during pregnancy, with pregnant individuals participating in RECOVER-Adult  
184 and offspring participating as the in utero exposed subgroup of RECOVER-Pediatric.

185           The broad objectives of both the RECOVER-Adult and RECOVER-Pediatric studies are  
186 to: (1) characterize the incidence and prevalence of sequelae of SARS-CoV-2 infection; (2)  
187 characterize the spectrum of clinical symptoms, subclinical organ dysfunction, natural history,  
188 and distinct phenotypes identified as sequelae of SARS-CoV-2 infection; (3) identify

189 demographic, social, and clinical risk factors for PASC and PASC recovery, and (4) define the  
190 biological mechanisms underlying pathogenesis of PASC.

191 The study protocols for both RECOVER-Adult and RECOVER-Pediatric cohorts are  
192 published separately.<sup>13,14</sup> The RECOVER-Pregnancy cohort is summarized here. The primary  
193 aims of the adult portion of the RECOVER-Pregnancy cohort include: (1) describing PASC  
194 onset, symptoms and severity by comparing pregnant individuals with SARS-CoV-2 with  
195 pregnant individuals without SARS-CoV-2, (2) characterizing risk factors for PASC onset,  
196 symptoms and severity following SARS-CoV-2 infection during pregnancy by comparing  
197 infected pregnant individuals with and without particular risk factors; and (3) evaluating if  
198 contracting SARS-CoV-2 in pregnancy is associated with a differential risk of developing PASC  
199 compared with non-pregnant individuals. The primary aims of the pediatric portion of the  
200 RECOVER-Pregnancy cohort include characterizing the clinical manifestations of exposure to  
201 SARS-CoV-2 infection during pregnancy on child physical health and behavioral and  
202 developmental outcomes, by comparing children with and without maternal history of SARS-  
203 CoV-2 infection during pregnancy.

## 204 **Study design and setting**

205 The NIH RECOVER study is a retrospective and prospective longitudinal meta-cohort  
206 study design in which individuals with and without exposure to SARS-CoV-2 infection are  
207 enrolled and followed over a maximum of 4 years. For RECOVER-Pregnancy, individuals with  
208 and without SARS-CoV-2 infection during pregnancy will be included. Individuals with a SARS-  
209 CoV-2 infection during pregnancy will be further classified as acute (infection within the past 30  
210 days at the time of enrollment) and post-acute (more than 30 days since infection). The  
211 RECOVER-Pregnancy cohort follows both the adult protocol and the part of the pediatric  
212 protocol that is specific to in utero exposure to SARS-CoV-2.

213 Mother-child dyads for the RECOVER-Pregnancy cohort are recruited in person at 12  
214 *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD)  
215 Maternal-Fetal Medicine Units (MFMU) Network Centers which include 26 individual hospital  
216 sites (encompassing community and academic hospitals) and remotely nationwide by the  
217 University of California San Francisco (UCSF). A list of study sites can be obtained at  
218 <https://recovercovid.org> or in Appendix 1. For participants recruited within the 26 individual  
219 hospital sites of the MFMU Network, recruitment occurs among individuals who were enrolled in  
220 the NICHD MFMU Gestational Research Assessments for COVID-19 (GRAVID) study<sup>15,16</sup>, a  
221 previously established cohort of individuals with and without SARS-CoV-2 during pregnancy  
222 over the COVID-19 pandemic, and new prospective enrollments of individuals with and without  
223 SARS-CoV-2 in pregnancy to encompass all variants of SARS-CoV-2. Study procedures for  
224 participants recruited by NICHD MFMU Network sites will be completed through a combination  
225 of remote survey assessments and in-person study visits. For those recruited remotely by the  
226 study team at the UCSF, recruitment occurs among individuals who were enrolled in the  
227 PRIORITY study, a previously established nationwide cohort of individuals with SARS-CoV-2  
228 during pregnancy, as well as through new nationwide outreach including social media outreach,  
229 referrals from the NIH RECOVER website, screening of the UCSF electronic health record and  
230 from RECOVER-Adult cohort sites that are not also participating in the pregnancy cohort.  
231 Participants recruited by UCSF will have study procedures such as anthropometric  
232 measurements and specimen collections completed during home visits while surveys are  
233 completed remotely. Individuals who are able to travel to UCSF may have study procedures  
234 completed in person. Participants can only be enrolled once to avoid overlap in recruitment  
235 across the RECOVER-Pregnancy sites.

## 236 **Study population**

237           Anyone with SARS-CoV-2 infection during pregnancy (defined as meeting World Health  
238 Organization criteria<sup>17</sup> for suspected, probable or confirmed SARS-CoV-2 infection), or with  
239 documented lack of SARS-CoV-2 exposure during pregnancy, irrespective of pregnancy  
240 outcome (loss, termination, or live birth) is eligible to enroll in RECOVER-Pregnancy (See  
241 RECOVER-Adult protocol for detailed definition).<sup>13</sup> The index date for infection is set as the date  
242 of the first infection as determined by the date of a positive SARS-CoV-2 test, or set at 90 days  
243 prior to antibody test date for those with positive antibodies who had an asymptomatic prior  
244 infection. Individuals with SARS-CoV-2 in pregnancies resulting in a live birth are only eligible  
245 for enrollment into one of the RECOVER pregnancy cohorts to facilitate co-enrollment of the  
246 offspring in the in utero exposure part of the pediatric protocol. Individuals with pregnancies  
247 resulting in pregnancy loss or termination are eligible to enroll at any adult cohort site.  
248 Pregnancies and pregnancy outcomes for all adults in the RECOVER-Adult cohort over the  
249 longitudinal follow-up period for RECOVER will also be recorded.

250           Those who had a pregnancy during the study enrollment window without SARS-CoV-2  
251 infection are eligible for enrollment as uninfected controls. Uninfected controls must have no  
252 reported history of SARS-CoV-2 infection, and be PCR negative and SARS-CoV-2 antibody  
253 negative at the time of enrollment. For the pregnancy cohort, index date for the post-acute  
254 uninfected controls is set at the date of delivery as the uninfected period of interest is the  
255 pregnancy (e.g. controls should not have been infected during pregnancy). The recruitment  
256 strategy seeks to have infected and uninfected individuals enrolled within the same time frame  
257 to reduce potential effects of societal modifications during the pandemic which may also affect  
258 neurodevelopment (e.g., social isolation, disruptions to education and childcare services,  
259 financial parental stressors, etc).<sup>18, 19</sup>

## 260 **Sample size**

261 Overall 2,300 adults with or without SARS-CoV-2 during pregnancy will be enrolled in  
262 RECOVER-Pregnancy along with their offspring. Of the 2300 pregnant individuals enrolled in  
263 the adult cohort, we plan to enroll 1867 infected with SARS-CoV-2 during pregnancy and 433  
264 uninfected during pregnancy. Because pregnant participants are enrolling as dyads with their  
265 offspring, we expect to enroll corresponding numbers of offspring exposed to SARS-CoV-2  
266 during pregnancy and unexposed during pregnancy, allowing for variability due to factors such  
267 as twins or multiple gestations and pregnancy loss. Of the adults enrolling in RECOVER-  
268 Pregnancy with SARS-CoV-2 infections, we plan for 15% of them to be enrolled during a period  
269 of acute infection (within 30 days of positive SARS-CoV-2 test).

270 For each comparison underlying the primary study objectives, we computed minimum  
271 effect sizes detectable with 90% power and a type-1 error rate of 0.01, for the full target sample  
272 sizes, as well as for only 25% of the overall cohort, as would be expected in a subgroup  
273 analysis. These results are also reported in Table 1. The minimum detectable PASC risk  
274 difference between pregnant participants with and without infection is 8.4% (15.8% in a 25%  
275 subgroup), assuming the risk of developing PASC among participants with infection is 25%.  
276 Assuming the prevalence of a given risk factor among pregnant participants with infection is  
277 20%, and the risk of PASC in pregnant participants with infection who have the risk factor is  
278 30%, the minimum detectable PASC risk difference between infected participants with and  
279 without the risk factor is 9.5% (17.4% in a 25% subgroup). Assuming 25% of non-pregnant adult  
280 participants are female and of reproductive age, the minimum detectable PASC risk difference  
281 between SARS-CoV-2 infected participants with and without active pregnancy at infection is  
282 4.7% (8.9% in a 25% subgroup). Finally, the minimum detectable difference in a continuous

283 biomarker or development score between offspring exposed to SARS-CoV-2 in utero and those  
 284 unexposed during pregnancy is 0.206 standard deviations (0.413 in a 25% subgroup).  
 285 Table 1. Sample size calculations for RECOVER-Pregnancy cohort (ES: effect size; RF: risk  
 286 factor; RF+: risk factor positive; SD: standard deviation)

Comparison groups		Effect of interest	Assumptions	Min. Detectable ES (90% power, 0.01 type I error rate)	
				Full Sample	25% Subgroup
Pregnant infected (n=1867)	Pregnant uninfected (n=433)	Difference in risk of PASC	Risk of PASC in infected: 25%	8.4%	15.8%
Pregnant infected w/ RF (n=373)	Pregnant infected w/out RF (n=1494)	Difference in risk of PASC	Prevalence of RF: 20% Risk of PASC in infected, RF+: 30%	9.5%	17.4%
Pregnant infected (n=1867)	Non-pregnant infected reproductive	Difference in risk of PASC	Risk of PASC in non-pregnant infected: 25%	4.7%	8.9%

	age female (n=3283)		25% of non-pregnant infected are reproductive age females		
Infant exposed in-utero (n=1867)	Infant not exposed in-utero (n=433)	Difference in continuous biomarker or development score	Equal variances	0.206 SDs	0.413 SDs

287

288           Importantly, adult RECOVER-Pregnancy cohort participants will be included in the  
289 planned primary analyses for RECOVER-Adult. Classification of adult pregnancy cohort  
290 participants will vary depending on the analysis being performed. For example, an adult  
291 participant who was uninfected during pregnancy will remain in the uninfected comparison  
292 group for all analyses examining outcomes of the offspring, as the offspring will not be exposed  
293 in utero. However, some of the enrolled adult pregnancy participants who were enrolled as  
294 uninfected controls will acquire SARS-CoV-2 infection during the 4-year longitudinal follow-up  
295 period. These participants will cross over to the infected group for the adult cohort, and will be  
296 analyzed as infected in analyses assessing only the adult outcomes from that time period  
297 forward, but their offspring will remain in the unexposed pediatric cohort. Thus, the RECOVER  
298 Data Resource Center (DRC) will classify pregnant individuals with SARS-CoV-2 and their  
299 offspring intentionally and separately for each analysis depending on the outcome being  
300 examined.

## 301 **Study procedures**

302 Details of protocol development are included separately in study protocol manuscripts  
303 for the RECOVER-Adult and RECOVER-Pediatric protocols.<sup>13,14</sup> Development of the pregnancy  
304 cohort study procedures and protocol occurred concurrently with the principal investigators for  
305 the pregnancy cohort participating in the development of both the RECOVER-Adult and  
306 RECOVER-Pediatric protocols. Study procedures for RECOVER-Adult are included in Figure 1.

307 Figure 1. Study procedures for RECOVER-Adult

308 A schematic of the relationship between pregnant individuals and their offspring, and the  
309 distribution of acute and post-acute SARS-CoV-2 infection is included in Figure 2. For adult  
310 participants, the pregnant cohort simply represents a predefined portion of the participants to  
311 ensure that PASC following SARS-CoV-2 infection during pregnancy can be examined and to  
312 examine differential effects when SARS-CoV-2 is acquired during pregnancy.

313 Figure 2. Schematic representation of planned enrollment for RECOVER-Pregnancy  
314 including pregnant individuals (both with and without SARS-CoV-2 during pregnancy) and the  
315 pediatric in utero exposure cohort. Acute infection is infection within the last 30 days and post-  
316 acute infection is infection during pregnancy, but at a time that was more than 30 days from the  
317 date of enrollment.

## 318 **Adult cohort**

319 The primary endpoint for the adult portion of the RECOVER-Pregnancy cohort mirrors  
320 that of the larger adult cohort and is defined as the presence of incident or prevalent candidate  
321 PASC symptoms over time. Secondary endpoints include biological and recovery trajectories  
322 from SARS-CoV-2 infection, documentation of organ injury, and incident clinical diagnoses.



323 Tier 1 RECOVER adult study procedures consist of completion of symptom surveys for a  
324 variety of PASC symptoms, height, weight and vital signs measurements, sit to stand and active  
325 stand evaluations, a core set of laboratory studies, and biospecimen collection. Each Tier 2 test  
326 is expected to be completed by approximately 30% of adult participants. Tier 2 testing can be  
327 triggered by abnormal values or responses in Tier 1; in addition, tier 2 testing is triggered in a  
328 randomly selected group of controls for comparison. Adult Tier 3 tests are both more invasive  
329 and more time consuming. Each tier 3 test is expected to be performed in approximately 20% of  
330 RECOVER participants. Participants may select to opt out of tier 2 and tier 3 tests without  
331 withdrawing from the study.

332 Adult participants in the pregnancy cohort complete all of the Tier 1 study procedures as  
333 defined in the adult cohort study design manuscript.<sup>13</sup> Similarly, pregnancy cohort participants  
334 are eligible for all of the Tier 2 and 3 study procedures with the exception of those detailed in  
335 Table 2 as these were felt to have unacceptable risk to the participant, the fetus, or neonate for  
336 this observational study. Similarly, triggers for some of the Tier 2 and Tier 3 tests have been  
337 modified for those who are pregnant, postpartum (within 3 months of delivery date), or  
338 breastfeeding as they would not be appropriate triggers during these time periods (Table 2). For  
339 example, weight loss is not used as a test trigger for participants who are postpartum as weight  
340 loss is anticipated postpartum.

341 Table 2. RECOVER-Adult study procedure modifications for pregnant, breastfeeding, or  
342 postpartum individuals

Tier of Test	Adult Study Procedure Modification	Excluded Population	Justification for Modification

Tier 2	Volumetric non-contrast chest CT	Pregnant and <3 months postpartum	Unacceptable risk of radiation exposure to the fetus without direct benefit
Tier 2	Dual energy chest CT with contrast	Pregnant and <3 months postpartum	Unacceptable risk of radiation exposure to the fetus without direct benefit
Tier 3	MRI brain with gadolinium	Pregnant and <3 months postpartum	Unacceptable risk of gadolinium exposure for fetus and neonate (via breastmilk) with no direct participant benefit
Tier 3	Cardiac imaging with meta-iodobenzylguanidine (mIBG)	Pregnant and <3 months postpartum	Unacceptable risk of mIBG exposure for fetus and neonate (via breastmilk) with no direct participant benefit
Tier 3	Gastric emptying study	Pregnant and <3 months postpartum	Physiologic changes in pregnancy and early postpartum period with gut motility precludes accurate interpretation
Tier 3	Skin biopsy	Pregnant and <3 months postpartum	Invasive procedure without direct participant benefit
Tier 3	Muscle biopsy	Pregnant and <3 months postpartum	Invasive procedure without direct participant benefit

Tier 3	Lumbar puncture	Pregnant and <3 months postpartum	Invasive procedure without direct participant benefit
Tier 3	Tilt table testing	Pregnant and <3 months postpartum	Physiologic changes in pregnancy and early postpartum period with vasodilatory response precludes accurate interpretation
Tier 3	Full cardiopulmonary exercise testing	Pregnant and postpartum	Exercise tolerance differs during pregnancy and early postpartum period which precludes accurate interpretation
Tier 3	Bronchoscopy	Pregnant and postpartum	Invasive procedure and anesthesia without direct participant benefit
Tier 3	Right heart catheterization	Pregnant and postpartum	Invasive procedure and anesthesia without direct participant benefit
Tier 3	Upper endoscopy	Pregnant and postpartum	Invasive procedure and anesthesia without direct participant benefit

Tier 3	Colonoscopy with or without biopsy	Pregnant and postpartum	Invasive procedure and anesthesia without direct participant benefit
Tier 3	Cardiac imaging with meta-iodobenzylguanidine (mIBG)	Breastfeeding	Unacceptable risk of contrast exposure to neonate through breastmilk with no direct participant benefit
Tier 3	Gastric emptying study	Breastfeeding	Unacceptable risk of contrast exposure to neonate through breastmilk with no direct participant benefit

343

344           Pregnancy characteristics and pregnancy outcome data will be ascertained by maternal  
345 self-report through survey questions following the end of pregnancy. The survey questions will  
346 be validated through manual medical record abstraction at the NICHD MFMU Centers as  
347 medical record data for participants are readily available at the Centers. Pregnancy  
348 characteristics and outcome data that will be collected are included in Box 1. Additional  
349 important covariates that are being collected include trimester of pregnancy at time of infection,  
350 severity of infection and treatment for infection.

<p>Box 1. Pregnancy Outcome Data Ascertained for RECOVER-Pregnancy Cohort</p> <p>Estimated date of delivery</p> <p>Actual delivery date</p> <p>Number of prior pregnancies and outcome of prior pregnancies</p> <p>Number of fetuses in index pregnancy (either infected or uninfected with SARS-CoV-2)</p>
---

Live birth, stillbirth, miscarriage, or termination

Birthweight of fetus(es)

Gestational diabetes

Hypertensive disorder of pregnancy

Cesarean birth

Diagnosis of intraamniotic infection

Placental abruption

Administration of magnesium sulfate

Administration of antenatal corticosteroids

Postpartum hemorrhage

ICU admission during delivery hospitalization

## 351 **Pediatric in utero exposure cohort**

352 All children will participate in Tier 1 assessments, which include broad health screening  
353 measures collected remotely via electronic surveys or telephone interviews, and Tier 2  
354 assessments, which include more in-depth clinical assessments conducted either at in-person  
355 visits or via videoconferencing. Tier 1 assessments occur at 12, 18, 24, 36 and 48 months of  
356 age, and Tier 2 assessments occur at 24, 36 and 48 months of age (Figure 3).

357 Figure 3. Study assessment schedule for children enrolled in RECOVER-Pregnancy or the in  
358 utero exposure cohort of RECOVER

359 Both Tiers 1 and 2 focus primarily on child developmental outcomes. Tier 1 includes  
360 developmental screening across the domains of communication, gross motor, fine motor,  
361 problem solving, and personal-social development using the Ages and Stages Questionnaire—  
362 3<sup>rd</sup> Edition (ASQ-3)<sup>20-22</sup>, social-emotional screening using the Ages and Stages Questionnaires:  
363 Social-Emotional, 2nd Edition (ASQ:SE-2) and standardized screening for Autism Spectrum

364 Disorder (ASD) using the Modified Checklist for Autism in Toddlers Revised with Follow up  
365 (MCHAT-RF)<sup>23</sup> (Figure 3). Child socioemotional and behavioral status will be assessed using  
366 the Child Behavior Checklist (CBCL)<sup>24</sup>. In addition, adaptive behavior, communication, cognitive  
367 development, social emotional development, and physical development, will be assessed using  
368 the Developmental Profile-4 (DP-4)<sup>25</sup> by direct caregiver interview (Figure 3).

369 Tier 2 assessments will include an evaluation of child development using the Bayley  
370 Scales of Infant and Toddler Development, 4th Edition (Bayley-4)<sup>26</sup> and the Differential Abilities  
371 Scales, 2<sup>nd</sup> Edition (DAS-II)<sup>27</sup>. The Bayley-4 is a comprehensive developmental assessment tool  
372 which will evaluate cognitive, language, and motor development for RECOVER. The DAS-II is a  
373 comprehensive assessment that provides insight into how a child processes information and  
374 problem-solving, related to verbal comprehension and nonverbal and spatial reasoning. Training  
375 for administration of the Bayley-4, DAS-II and DP-4 will be conducted centrally by the  
376 RECOVER Clinical Science Core (CSC) Neurocognitive Leadership Team, and videos of mock  
377 administrations will be reviewed for all examiners to ensure validity of the administered exam  
378 prior to performing any exams for the purposes of the RECOVER study.

379 In addition to the neurocognitive outcomes, broader child health outcomes are assessed  
380 as well. Tier 1 surveys assess sociodemographic information, medical history and special health  
381 care needs using items from the National Surveys of Children's Health<sup>28</sup>, SARS-CoV-2 infection  
382 history, related conditions (e.g., Multisystem inflammatory syndrome in children (MIS-C),  
383 Postural Orthostatic Tachycardia Syndrome, and Long COVID diagnoses), COVID-19 testing  
384 and vaccine history, COVID-19-related symptoms (acute and long-term), COVID-19 health  
385 consequences (e.g., diet, physical activity, sleep, screen time, schooling, parenting) and social  
386 determinants of health (e.g., early childhood experiences or stressors). Brief infant Sleep  
387 Questionnaire (BISQ)<sup>29</sup> is also collected at 24 months of age.

388 Other Tier 2 assessments include anthropometric measurements, such as child weight,  
389 length/height, and head circumference measured using well calibrated, quality instruments and  
390 standardized techniques, to ultimately assess child weight trajectories, weight status and  
391 cardiometabolic risk. A sample of blood will be obtained at 24 months for SARS-CoV-2 antibody  
392 testing and central biobanking. Blood will be collected at 24 months by a trained and  
393 experienced pediatric phlebotomist, or through remote at-home collection using a TASSO M20  
394 device, which collects capillary blood using 4 volumetric sponges that each hold 17.5µL of blood  
395 (70 µL total). If using the Tasso M20 device, one sponge is used for SARS-CoV-2 spike and  
396 nucleocapsid antibody testing and remaining sponges are banked for future use. If using in-  
397 person phlebotomy, EDTA and SST tubes will be collected ensuring that the total blood volume  
398 is less than 2 mL per kg of body weight.

## 399 **Data collection, management and quality assurance**

400 All data are collected through secure entry into a single instance of REDCap  
401 created by the RECOVER DRC. Oversight of data and safety is provided by the RECOVER  
402 Observational Safety Monitoring Board (OSMB) appointed by the National Institutes of Health  
403 (NIH). The purpose of the OSMB is to assure independent review as to whether study patients  
404 are exposed to unreasonable risk because of study participation, and to monitor study progress  
405 and integrity. Data collection and quality assurance are further detailed in the RECOVER-Adult  
406 cohort study design manuscript.<sup>13</sup>

## 407 **Statistical analysis**

408 The point prevalence of PASC symptoms, defined as the proportion of participants  
409 reporting a symptom at a given follow-up time point among those remaining in RECOVER, will

410 be calculated across the follow-up period for participants with infection during pregnancy and  
411 without infection during pregnancy, both overall and among those whose pregnancy has ended  
412 (termination, miscarriage, or delivery). Odds ratios (ORs) adjusted for demographic factors will  
413 be reported. A paradigm for identifying PASC cases will be developed in the broader adult  
414 cohort as described in the RECOVER-Adult study design paper, and evaluated in the population  
415 with SARS-CoV-2 infection during pregnancy along with alternative clinically-derived PASC  
416 definitions.

417 Logistic regression analyses will be conducted to investigate associations between  
418 cumulative incidence of PASC and clinical factors, demographics, and social determinants of  
419 health among participants with infection during pregnancy, as well as comparing those infected  
420 during pregnancy with infected non-pregnant reproductive age females. Sensitivity analyses  
421 assessing the influence of pregnancy factors such as gestational age at infection, and timing of  
422 follow-up visits relative to the end of pregnancy, will be considered.

423 Measures of child physical health and behavioral and developmental outcomes will be  
424 summarized in the in utero exposure to SARS-CoV-2 cohort overall and by maternal infection  
425 status during pregnancy. Two-sample, two-sided t-tests will be used to compare cross-sectional  
426 means of continuous outcomes between groups, and chi-squared tests will be used to compare  
427 categorical outcomes between groups. Multivariable linear and generalized linear regression  
428 models will also be fit to adjust for relevant baseline factors that are different between groups.  
429 For outcomes measured at multiple visits, trajectories will be modeled and compared using  
430 linear and generalized linear mixed effects models.

## 431 **Safety and possible risks**

432 All RECOVER activities are approved by a single institutional review board (IRB), which  
433 is the New York University IRB. All of the RECOVER-Pregnancy sites will establish reliance on



434 the single IRB for RECOVER. Any protocol modifications will be approved by the single IRB and  
435 communicated with all RECOVER investigators and research staff by the CSC. Written informed  
436 consent will be obtained for all participants by research personnel at participating RECOVER-  
437 Pregnancy sites. Participants will have the opportunity to opt out of storage of specimens for  
438 future use and for genetic analyses.

439 For both the pediatric and adult cohort portions of the pregnancy cohort, results from  
440 laboratory testing and other tests performed as study procedures are monitored centrally by the  
441 CSC, DRC, and the individual site PIs along with their research teams. For each lab result, the  
442 research team determines if the result is normal and abnormal, and if abnormal whether it is  
443 clinically actionable. For pregnant participants, many of the laboratory results fall outside of  
444 established lab normal values; yet, are normal for pregnant individuals. Thus, thresholds for  
445 clinical action differ for this special population and the need for clinical action will be determined  
446 by the investigators at each site who are obstetricians or maternal-fetal medicine subspecialists.

447 If the neurodevelopmental test score or social emotional score falls in a range where  
448 additional monitoring or referral are recommended, results of screening tests completed in Tier  
449 1 (ASQ-3, ASQ:SE-2, MCHAT R/F) or assessment tests completed in Tier 2 (Bayley-4, DAS-II  
450 and DP-4) will be provided to the caregiver of the participant with a recommendation to follow-  
451 up with the child's primary health care provider. Ranges of concern will be determined by  
452 psychologists and developmental-behavioral pediatricians, and standardized across the cohort.

## 453 **Discussion**

454 The NIH RECOVER-Pregnancy cohort will answer critical questions regarding the  
455 incidence and trajectory of PASC following SARS-CoV-2 infection during pregnancy, and the  
456 effects of in utero exposure to SARS-CoV-2 infection on offspring development. There are little

457 data regarding the incidence of PASC in a population who acquired SARS-CoV-2 during  
458 pregnancy. Initial data from the PRIORITY Registry suggest persistence of symptoms among  
459 pregnant individuals for weeks to months after SARS-CoV-2 infection.<sup>5</sup> As pregnant individuals  
460 have alterations in inflammatory response and hormone levels, and have been noted to have an  
461 increased risk of severe or critical illness with SARS-CoV-2 infection, it is plausible that the rates  
462 of PASC could be different in this group.<sup>4,30,31</sup> Differences in the prevalence or symptoms of  
463 PASC among those who acquire SARS-CoV-2 in pregnancy compared with non-pregnant  
464 individuals could help with determination of the underlying pathophysiology of PASC.

465         Recent research suggests that being born during the pandemic is associated with lower  
466 scores on neurodevelopmental screening than in historical controls; however, exposure to  
467 SARS-CoV-2 infection alone was not associated with a difference from unexposed children  
468 living through the pandemic.<sup>18,19</sup> A large administrative database study by Edlow and colleagues  
469 found an association between exposure to SARS-CoV-2 in utero and neurodevelopmental  
470 diagnoses, but was limited by the possibility of ascertainment bias, because those exposed to  
471 SARS-CoV-2 may have been more likely to be followed and referred.<sup>32</sup> The RECOVER-  
472 Pregnancy study will add to this available evidence by comparing children who were SARS-  
473 CoV-2 exposed with contemporaneous unexposed controls, and following them longitudinally  
474 over time. The RECOVER-Pregnancy study will also be able to examine for potential  
475 differences in subsets of the population exposed to SARS-CoV-2 in utero, such as by trimester  
476 of infection, or by maternal disease severity and treatments for SARS-CoV-2.

477         The design of the pregnancy cohort provides several strengths. Enrollment of maternal-  
478 child dyads across the U.S. will increase generalizability of study results, enhance racial, ethnic,  
479 and socioeconomic diversity, and enable collection of detailed information on both the mother  
480 and the child to enable robust analyses. SARS-CoV-2 is known to have disproportionately  
481 affected Black and Latino communities (especially early in the pandemic)<sup>33, 34</sup>; thus, the

482 RECOVER-Pregnancy investigators are committed to reaching a diverse population for studying  
483 the long-term effects of contracting SARS-CoV-2 in pregnancy. Individuals with pregnancies  
484 across the time period of the COVID-19 pandemic will be included allowing for comparisons by  
485 major SARS-CoV-2 variants, which are known to differentially affect pregnancy outcomes.<sup>7,8</sup>  
486 Allowing both in-person and remote assessments may help reach participants who could not  
487 participate in one or the other types of study visits. Developmental and socioemotional-  
488 behavioral screening and direct neurodevelopmental assessments will be performed by  
489 centrally trained and certified study personnel.

490 Our study design has several important limitations. First, since study procedures are  
491 extensive and require significant time, families who have less availability to attend study visits  
492 may be less likely to enroll in or more likely to be lost to follow up. This could reduce the  
493 generalizability of our results. In addition, because participants born at any time during the  
494 pandemic are eligible for enrollment, participants born earlier in the pandemic will not be able to  
495 be assessed for outcomes measured by the study at ages prior to their date of enrollment; thus,  
496 we will have smaller sample sizes available for some of the pediatric outcomes.

497 We anticipate that further modifications to the protocol will be made as the COVID-19  
498 pandemic evolves and the scientific community learns more about both PASC and the effects of  
499 exposure to SARS-CoV-2 in utero on offspring. Nonetheless we have designed a rigorous study  
500 to evaluate the effect of SARS-CoV-2 on maternal-child dyads and anticipate that it will  
501 substantially further scientific understanding of the risks of contracting SARS-CoV-2 while  
502 pregnant.

## 503 **Acknowledgements**

504           We would like to thank the National Community Engagement Group (NCEG), all patient,  
505 caregiver and community representatives, and all the participants enrolled in the RECOVER  
506 initiative.

507           Membership of the RECOVER Initiative is provided in a supplemental appendix file.

## 508 **Supporting Information**

509           The supporting information is provided in a supplemental appendix file.

## 511 References

- 512 1. Ballering AV, van Zon SKR, Hartman TCO, Rosmalen JGM. Persistence of somatic  
513 symptoms after COVID-19 in the Netherlands: an observational cohort study. *Lancet*  
514 2022; 400: 452-61.
- 515 2. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19.  
516 *JAMA* 2020; 324(6): 603-05.
- 517 3. Bull-Otterson L. Post-COVID conditions among adult COVID-19 survivors aged 18-64  
518 and  $\geq 65$  years old – United States, March 2020–November 2021. *MMWR* 2021; 71:713.
- 519 4. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms  
520 and recommendations. *Nat Reviews Microbiology* 2023; 21: 133-146.
- 521 5. Afshar Y, Gaw SL, Flaherman VJ, et al. Clinical presentation of coronavirus disease  
522 2019 (COVID-19) in pregnant and recently pregnant people. *Obstet Gynecol* 2020;  
523 136(6):1117-25.
- 524 6. Schwartz DA, Avvad-Portari E, Babal P, et al. Placental tissue destruction and  
525 insufficiency from COVID-19 causes stillbirth and neonatal death from hypoxic-ischemic  
526 injury: a study of 68 cases with SARS-CoV-2 placentitis from 12 countries. *Arch Pathol*  
527 *Lab Med* 2022; 146(6):660-76.
- 528 7. Seasely AR, Blanchard CT, Arora N, et al. Maternal and Perinatal Outcomes Associated  
529 With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-  
530 CoV-2) Infection. *Obstet Gynecol* 2022;140(2):262-265.
- 531 8. Adhikari EH, SoRelle JA, McIntire DD, Spong CY. Increasing severity of COVID-19 in  
532 pregnancy with Delta (B.1.617.2) variant surge. *Am J Obstet Gynecol* 2022;226(1):149-  
533 151.
- 534 9. Stock SJ, Carruthers J, Calvert C, et al. SARS-CoV-2 infection and COVID-19  
535 vaccination rates in pregnant women in Scotland. *Nat Med* 2022;28(3):504.
- 536 10. Hui L, Marzan MB, Rolnik DL, et al. Reductions in stillbirths and preterm birth in COVID-  
537 19-vaccinated women: a multicenter cohort study of vaccination uptake and perinatal  
538 outcomes. *Am J Obstet Gynecol* 2022; epub ahead of print.
- 539 11. Morgan JA, Biggio JR, Jr., Martin JK, et al. Maternal Outcomes After Severe Acute  
540 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Vaccinated Compared  
541 With Unvaccinated Pregnant Patients. *Obstet Gynecol* 2022;139(1):107-109.
- 542 12. Hughes BL, Sandoval GJ, Metz TD, et al. First- or second-trimester SARS-CoV-2  
543 infection and subsequent pregnancy outcomes. *Am J Obstet Gynecol* 2022; epub  
544 ahead of print.
- 545 13. Horwitz L, et al. National Institutes of Health REsearching COVID to Enhance Recovery  
546 (RECOVER) Adult Cohort: Rationale, Objectives, and Study Design; submitted  
547 concurrently.

- 548 14. Gross R, et al. National Institutes of Health REsearching COVID to Enhance Recovery  
549 (RECOVER) Pediatric Cohort: Rationale, Objectives, and Study Design; submitted  
550 concurrently.
- 551 15. Metz TD, Clifton RG, Hughes BL, et al for the National Institute of Child Health and  
552 Human Development Maternal-Fetal Medicine Units (MFMU) Network. Association of  
553 SARS-CoV-2 Infection with Serious Maternal Morbidity and Mortality from Obstetric  
554 Complications. *JAMA* 2022; 327(8):748-59.
- 555 16. Metz TD, Clifton RG, Hughes BL, et al for the National Institute of Child Health and  
556 Human Development Maternal-Fetal Medicine Units (MFMU) Network. Association  
557 Between Giving Birth During the Early Coronavirus Disease 2019 (COVID-19) Pandemic  
558 and Serious Maternal Morbidity. *Obstet Gynecol* 2023; 141(1):109-118.
- 559 17. World Health Organization. WHO COVID-19: case definitions, updated in public health  
560 surveillance for COVID-19, 22 July 2022. [https://www.who.int/publications/i/item/WHO-](https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2022.1)  
561 [2019-nCoV-Surveillance Case Definition-2022.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2022.1). Accessed March 9, 2023.
- 562 18. Shuffrey LC, Firestein MR, Kyle MH, et al. Association of Birth During the COVID-19  
563 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In  
564 Utero Exposure to Maternal SARS-CoV-2 Infection. *JAMA Pediatr*. Published online  
565 January 4, 2022:e215563. doi:10.1001/jamapediatrics.2021.5563
- 566 19. Huang P, Zhou F, Guo Y, et al. Association Between the COVID-19 Pandemic and  
567 Infant Neurodevelopment: A Comparison Before and During COVID-19. *Front Pediatr*.  
568 2021;9:662165. doi:10.3389/fped.2021.662165
- 569 20. Squires J, Bricker D. Ages & Stages Questionnaires®, Third Edition (ASQ®-3): A  
570 Parent-Completed Child Monitoring System. Baltimore: Paul H. Brookes Publishing Co.,  
571 Inc; 2009.
- 572 21. Squires J, Bricker D, Potter L. Revision of a parent-completed development screening  
573 tool: Ages and Stages Questionnaires. *J Pediatr Psychol*. 1997;22(3):313-328.
- 574 22. Squires J, Twombly E, Bricker D, L P. Ages & Stages Questionnaires®, Third Edition  
575 (ASQ®-3): Technical Report. Baltimore: Paul H. Brookes Publishing Co., Inc; 2009.
- 576 23. Robins DL, Casagrande K, Barton M, Chen CM, Dumont-Mathieu T, Fein D. Validation  
577 of the modified checklist for Autism in toddlers, revised with follow-up (M-CHAT-R/F).  
578 *Pediatrics*. 2014;133(1):37-45.
- 579 24. Achenbach TM and Rescorla LA. Manual for the ASEBA school-age forms & profiles: an  
580 integrated system of multi-informant assessment. Burlington: University of Vermont,  
581 Research Center for Children, Youth & Families; 2001.
- 582 25. Alpern GD. Developmental Profile 4 (DP-4). WPS. [https://www.wpspublish.com/dp-4-](https://www.wpspublish.com/dp-4-developmental-profile-4.html)  
583 [developmental-profile-4.html](https://www.wpspublish.com/dp-4-developmental-profile-4.html). Accessed March 9, 2023.
- 584 26. Bayley N and Aylward GP (2019). Bayley Scales of Infant and Toddler Development (4<sup>th</sup>  
585 Ed) technical manual. Bloomington, MN: NCS Pearson.
- 586 27. Elliott CD. Manual for the Differential Ability Scales, Second Edition. San Antonio, TX:  
587 Harcourt Assessment; 2007.

- 588 28. Ghandour RM, Jones JR, Lebrun-Harris LA, et al. The design and implementation of the  
589 2016 National Survey of Children's Health. *Matern Child Health J* 2018; 22(8):1093-  
590 1102.
- 591 29. Sadeh A. A brief screening questionnaire for infant sleep problems: validation and  
592 findings of an internet sample. *Pediatrics* 2004; 113(6): e570-7.
- 593 30. Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long  
594 COVID in non-hospitalized adults. *Nature Medicine* 2022; 28:1706-1714.
- 595 31. Saadedine M, El Sabeh M, Borahay MA, Daoud G. The influence of COVID-19 infection-  
596 associated immune response on the female reproductive system. *Biology of*  
597 *Reproduction* 2023; 108(2):172-182.
- 598 32. Edlow AG, Castro VM, Shook LL, Kaimal AJ, Perlis RH. Neurodevelopmental outcomes  
599 at 1 year in infants of mothers who tested positive for SARS-CoV-2 during pregnancy.  
600 *JAMA Netw Open* 2022; 5(6):e2215787.
- 601 33. Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and Racial/Ethnic  
602 Disparities. *JAMA* 2020;323(24):2466-2467.
- 603 34. Burris HH, Mullin AM, Dhudasia MB, et al. Neighborhood Characteristics and Racial  
604 Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)  
605 Seropositivity in Pregnancy. *Obstet Gynecol* 2022;139(6):1018-1026.

606

607

608

609

610

eCRF	Baseline	Time Point after index date															
		3m	6m	9m	12m	15m	18m	21m	24m	27m	30m	33m	36m	39m	42m	45m	48m
Enrollment	●																
Tier 1-2 Consent	●																
Identity	●																
Visit	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Comorbidities	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
COVID Treatment*	●																
Medications	●																
Change in Medications		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Demographics	●																
PASC Symptoms	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Vaccination Status	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Social Determinants of Health	●																
Social Determinants Follow-up		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Alcohol/Tobacco	●																
Alcohol/Tobacco Follow-up		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Disability	●																
Pregnancy	●																
Pregnancy Follow-up		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Tier 1 office visit	●		●		●				●			●					●
Biospecimens	●	●	●		●				●			●					●
Lab Results	●	●	●		●				●			●					●
Tier 2/Tier 3 Tests		●															

\* COVID Treatment not collected on people without infection

**Legend**

- Completed by research coordinator
- Completed by participant
- Completed by research coordinator with review/validation by participant

Figure 1






Figure 2




Figure 3